Extrawell Pharmaceutical Holdings Limited (00858) reported that its authorized share capital stood at 20.00 billion ordinary shares at a par value of HKD 0.01, totaling HKD 200.00 million as of February 2026. The issued share capital also remained unchanged at 2.55 billion shares.

According to the announcement, 76.50 million share options were outstanding under the share option scheme adopted on 2 September 2022, with a potential total of 162.50 million shares that may be issued upon full exercise. Additionally, the company reported zero-coupon convertible bonds of HKD 577.17 million, convertible at HKD 0.64 per share, potentially leading to up to 900.00 million new shares. The company confirmed that it satisfied the 25% public float requirement.